Incidence of interstitial lung disease (ILD) and risk factors for developing ILD: A final analysis of a large-scale erlotinib Japanese surveillance study in non-small-cell lung cancer (NSCLC)
H. Taniguchi, S. Kudoh, M. Ando, Y. Ohe, K. Nakagawa, H. Arakawa, M. Ebina, Y. Inoue, A. Gemma, M. Kusumoto, K. Kuwano, F. Sakai, T. Johkoh, Y. Fukuda, Y. Kiyohara, N. Yamazaki, A. Seki, M. Fukuoka (Seto, Tokyo, Nagoya, Kashiwa, Osaka, Tochigi, Sendai, Saitama, Hyogo, Shizuoka, Japan)
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Disease area: Thoracic oncology
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. Taniguchi, S. Kudoh, M. Ando, Y. Ohe, K. Nakagawa, H. Arakawa, M. Ebina, Y. Inoue, A. Gemma, M. Kusumoto, K. Kuwano, F. Sakai, T. Johkoh, Y. Fukuda, Y. Kiyohara, N. Yamazaki, A. Seki, M. Fukuoka (Seto, Tokyo, Nagoya, Kashiwa, Osaka, Tochigi, Sendai, Saitama, Hyogo, Shizuoka, Japan). Incidence of interstitial lung disease (ILD) and risk factors for developing ILD: A final analysis of a large-scale erlotinib Japanese surveillance study in non-small-cell lung cancer (NSCLC). Eur Respir J 2013; 42: Suppl. 57, 5124
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: